OncoMatch/Clinical Trials/NCT07730515
Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma
Is NCT07730515 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including XNW5004 combined with CHOP (incremental) and XNW5004 combined with CHOEP (incremental) for non-hodgkin lymphoma.
Treatment: XNW5004 combined with CHOP (incremental) · XNW5004 combined with CHOEP (incremental) · XNW5004 combined with CHOP (extended) · XNW5004 combined with CHOEP (extended) — In this study, the XNW5004 tablets combined with CHOP/CHOEP will be used for the treatment of newly diagnosed PTCL patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic anti-PTCL therapy
No prior systemic anti-PTCL therapy
Cannot have received: anti-tumor therapy
Prior treatment with any anti-tumor therapy, including but not limited to: chemotherapy, immunotherapy, radiotherapy, targeted therapy, anti-tumor traditional Chinese medicine, or anti-tumor investigational drugs
Lab requirements
Blood counts
White blood cell count >= 3.5 x 10^9/L (no G-CSF administration within 1 week before the screening blood test, and no long-acting leukocyte-elevating agent administration within 2 weeks); Platelet count >= 75 x 10^9/L (no platelet transfusion or TPO receptor agonist administration within 1 week before the screening blood test); Hemoglobin >= 80 g/L (no red blood cell transfusion or EPO administration within 1 week before the screening blood test)
Kidney function
serum creatinine <= 1.5 x ULN or estimated creatinine clearance >= 60 mL/min according to the Cockcroft-Gault formula
Liver function
serum total bilirubin <= 1.5 x ULN (<= 3 x ULN for Gilbert's syndrome), and ALT and AST <= 2.5 x ULN; for subjects with liver infiltration, ALT/AST <= 5 x ULN; for subjects with liver and/or bone infiltration, alkaline phosphatase <= 5 x ULN
Cardiac function
Left ventricular ejection fraction (LVEF) >= 50%
Vital organ function reserves meet the following requirements: Hematopoietic function: White blood cell count >= 3.5 x 10^9/L... Platelet count >= 75 x 10^9/L... Hemoglobin >= 80 g/L... Hepatic function: serum total bilirubin <= 1.5 x ULN (<= 3 x ULN for Gilbert's syndrome), and ALT and AST <= 2.5 x ULN; for subjects with liver infiltration, ALT/AST <= 5 x ULN; for subjects with liver and/or bone infiltration, alkaline phosphatase <= 5 x ULN. Renal function: serum creatinine <= 1.5 x ULN or estimated creatinine clearance >= 60 mL/min according to the Cockcroft-Gault formula. Left ventricular ejection fraction (LVEF) >= 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07730515 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages